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Abstract
Background. Patients with chronic kidney disease (CKD)
often present with iron depletion and iron deficiency an-
aemia (IDA) because of frequent blood (and iron) loss.
Therapy consists of repletion of iron stores and intraven-
ous (i.v.) iron has become the standard care in this set-
ting. However, older i.v. iron preparations have their
limitations. This study primarily investigated the safety,
and also the efficacy, of ferric carboxymaltose (FCM), a
next-generation i.v. iron formulation, given as a bolus–push
injection in patients with CKD undergoing maintenance
haemodialysis (HD).
Methods. Patients (aged 18–65 years) with IDA undergo-
ing HD received 100–200 mg of iron as FCM via an i.v.
bolus–push injection into the HD venous line, two to three
times weekly for ≤6 weeks. Safety assessments included
incidence of adverse events (AEs). Treatment responders
were patients attaining ≥1.0 g/dl increase in haemoglobin
(Hb) from baseline at any time during the study. Enrolled
patients (safety population) receiving ≥1 dose of study
medication were included in the efficacy analyses [intent-
to-treat (ITT) population].
Results. Of 163 patients enrolled, 150 (92%) completed
the study. The mean ± SD total cumulative dose of iron
as FCM administered was 2133.3 ± 57.7 mg. In total,
193 AEs were reported in 89 out of 163 (54.6%) patients.
Almost three-quarters of patients (73.6%) received
erythropoiesis-stimulating agents (ESAs), but the dose re-
mained stable during the study. Serious AEs occurred in
12 out of 163 (7.4%) patients and two patients died; none
of these was considered by the investigator to be related to
the study medication. Only five out of 163 (3.1%) patients
discontinued study medication due to an AE. Overall, 100
out of 162 (61.7%; ITT population) patients were treatment
responders,andmeanHblevelsincreasedfrom9.1±1.30g/
dl at baseline to 10.3 ± 1.63 g/dl at follow-up.
Conclusions. FCM is well-tolerated and effective in the
correction of Hb levels and iron stores in patients with
IDA undergoing HD. As changes in anaemia treatment
other than i.v. FCM (e.g. increased ESA doses) were not
permitted during the study, the clinically relevant increase
in Hb in the majority of patients can be solely attributed to
efficient iron utilization. The incidence of AEs was as ex-
pected for this population.
Keywords: clinical trial; efficacy; ferric carboxymaltose; haemodialysis;
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Introduction
Annual blood losses of around 2.5 l place patients with
chronic kidney disease (CKD) undergoing haemodialysis
(HD) at particularly high risk of iron store depletion with
subsequent iron deficiency anaemia (IDA) [1,2]. Iron de-
ficiency can be defined as absolute or functional [1,3]. Ab-
solute iron deficiency develops as the body's iron stores
become depleted to such a low level that not enough iron
is available for the production of haemoglobin (Hb) [4,5].
This is usually indicated by a decline in serum ferritin le-
vels to ∼<15 μg/l in patients with normal kidney function,
but is much higher in patients undergoing HD as a result of
chronic inflammation, and is associated with elevated le-
vels of C-reactive protein (CRP) [4,5]. This functional iron
deficiency describes the state when iron cannot be mobi-
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meet the demand for erythropoiesis [4]. Serum ferritin le-
vels can appear normal (200–500 μg/l) or increased in
chronic inflammatory disorders [4], while levels of trans-
ferrin saturation (TSAT), which is serum iron divided by
total iron-binding capacity, will be low (typically <20%),
indicating limited transport of iron to the erythron for
erythropoiesis [4].
The primary therapeutic aim in anaemic patients under-
going HD is to restore Hb levels and iron stores to inter-
nationally recommended target ranges. To attain the Hb
target range of 11.0–12.0 g/dl (not exceeding 13.0 g/dl),
patients are given supplemental intravenous (i.v.) iron as
an adjunct to erythropoiesis-stimulating agents (ESAs)
[1,6]. For patients undergoing HD, i.v. iron substitution
is the recommended route of administration [1] and has be-
come the standard treatment for optimizing a patient's iron
status [3,7]. Nevertheless, older i.v. iron formulations have
their limitations, including the potential for immunogenic
reactions induced by dextran molecules (iron dextran) [8],
dose limitations, a slow rate of administration (to prevent
acute, labile iron-induced toxicity and vasoactive reac-
tions) [4,8] and the compulsory requirement for a test dose
(iron dextrans in USA [9, 10] and Europe [11]). All-event
reporting rates were 29.2, 10.5 and 4.2 reports per million
100 mg iron dose equivalents, while all-fatal-event report-
ing rates were 1.4, 0.6 and 0.0 reports per million 100 mg
dose equivalents for iron dextran, sodium ferric gluconate
and iron sucrose, respectively [12].
Ferric carboxymaltose [FCM; Ferinject®; Vifor (Inter-
national) Inc., St Gallen, Switzerland] is a next-generation
parenteral, dextran-free iron formulation designed to over-
come the limitations of existing i.v. iron preparations. The
FCM complex is composed of a polynuclear iron(III) hy-
droxide complexed to carboxymaltose [13]. As FCM is a
strong and robust iron complex, it can be administered in
high doses, does not release large amounts of reactive
(‘free’) iron into the circulation and does not trigger dex-
tran-associated immunogenic reactions [13].
In a pharmacokinetics study of six patients by Beshara
et al., no adverse events (AEs) were experienced by any
of the patients following the administration of 100 mg of
iron as FCM [14]. A Phase I pharmacokinetics and dose-
escalation study of 32 patients with mild IDA demon-
strated that up to 1000 mg iron administered as an i.v.
infusion of FCM over 15 min is well-tolerated [15].
Here, we report the results of a multi-centre, open-label,
single-arm, Phase II study designed to assess the safety
and efficacy of multiple doses of i.v. iron as FCM, given
as single, bolus–push injections in the correction of IDA in
patients undergoing HD.
Materials and methods
Patients
Patients (aged 18 to 65 years) with IDA (Hb ≤11.0 g/dl and either serum
ferritin ≤200 μg/l or TSAT <20%), undergoing maintenance HD two to
three times per week, were recruited from 24 study centres across three
countries (11 centres in South Africa, eight in Romania and five in Lithu-
ania). Patients' iron status (serum ferritin, TSAT, serum iron and serum
transferrin) was assessed up to 7 days before study commencement to
justify inclusion. Patients had to be clinically stable without a hospital
admission due to renal decompensation during the 4 weeks prior to study
inclusion, and a permanent vascular access appropriate for HD was re-
quired. Concomitant administration of ESAs was permitted during the
study, provided that the patients had started treatment at least 1 month
prior to study inclusion and remained on stable doses throughout the trial.
Women of childbearing age had to use reliable forms of contraception
throughout the study and for up to 1 month after the final dose of study
medication. All patients provided written, informed consent before par-
ticipating in the study.
Exclusion criteria were: a Hb level <6.5 g/dl, serum ferritin level
>500 μg/l, TSAT >50% or serum albumin <2.5 g/dl; known hypersensi-
tivitytoironpolysaccharidecomplexesortoFCM;vitaminB12orfolicacid
deficiency;anyothertypeofanaemia;evidenceof ironoverloadconditions
(e.g. haemochromatosis); significant cardiovascular disease (including
myocardialinfarctionduringthe6monthspriortostudyinclusion,congest-
iveheartfailureNewYorkHeartAssociationIIIorIVandpoorlycontrolled
hypertension);uncontrolledendocrinologicalormetabolicdisorders;active
infection, malignancy, active liver disease, active peptic ulcer, asthma or
rheumatoid arthritis; pregnancy or lactation; a history of alcohol or drug
abuse; a positive hepatitis B surface antigen or antibody anti-hepatitis C
virus test; the need for blood transfusion within 2 months of the start of
thestudy,surgery(withtheexceptionofsurgeryrelatedtovascularaccess),
treatmentwithoralori.v.ironpreparationsoranyinvestigationaldrugwith-
in 4 weeks prior to study enrolment.
Study design and treatment
The primary objective of this trial was to assess the safety of i.v. iron
supplementation as FCM in anaemic patients undergoing HD. The sec-
ondary objective was to evaluate the efficacy of FCM in correcting iron
deficiency and Hb levels in this patient population. This study was con-
ducted in compliance with the guidelines for Good Clinical Practice and
other regulatory requirements.
Eligible patients received 100–200 mg of iron as FCM administered as
an i.v. bolus–push injection into the HD venous line 1 h after the start of
each dialysis session (two to three sessions per week) for a maximum of 6
weeks. This dose has been found to bewell-tolerated when administered as
an i.v. infusion of iron sucrose to patients with renal anaemia [16]. The
total cumulative dose of iron given to a patient depended on the patient's
individual iron deficit (Ganzoni formula: Iron deficit [mg] = b.w. [kg] ×
(target Hb − actual Hb) [g/dl] × 2.4 + depot iron [mg] where b.w. is body
weight, Hb is haemoglobin, target Hb = 15 g/dl, factor 2.4 = 0.0034 (iron
content Hb ≅ 0.34%) × 0.07 (blood volume ≅ 7% of b.w.) × 1000 (con-
version grammes to milligrammes) × 10 (conversion litre to decilitre), and
depot iron is 500 mg for patients ≥35 kg body weight. In patients with a
bodymassindex(weight[kg]/(height[m] ×height[m]))>25, anormalized
weight was used to calculate the iron deficit. For patients <66 kg, the cal-
culated cumulative dose is rounded down to the nearest 100 mg. For pa-
tients >66 kg, the calculated cumulative dose is rounded up to the nearest
100 mg. Normalized weight [kg] = 25 × height [m] × height [m].) [17]. A
maximum of 600 mg iron wasadministeredweekly;thecumulativemax-
imum dose of FCM did not exceed 2400 mg of iron. Study medication was
halted if serum ferritin levels exceeded 500 μg/l or TSATwas >50%. Fol-
lowing the final administration of study medication, patients entered an
observation period for up to 1 month. Patient assessments took place
every 2 weeks from baseline, with a final follow-up assessment at the
end of the observation period. For some patients who withdrew or dis-
continued early, the follow-up visit took place as soon as possible after-
wards, irrespective of the week of final medication.
Assessments
Safetyandtolerability were assessedby the incidence, severity andrelation
tostudymedicationof AEs,recordedbytheinvestigatorfromthefirstdose
ofFCM.Alsomonitoredwereroutineclinicallaboratorysafetyparameters,
vital signs and physical parameters [including 12-lead electrocardiogram
(ECG) measurements], CRP and pre- and post-dialysis serum urea values.
Efficacy was assessed by correction of patients' iron stores and Hb
levels; no primary efficacy endpoint was defined. Treatment responders
were defined as patients who exhibited an increase of ≥1.0 g/dl in Hb
from baseline at any point during the study. All laboratory parameters
were determined at local laboratories in each country, and all iron para-
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study. Only results from the central laboratory were included in the stat-
istical analyses.
Statistical analyses
Thiswas a single-arm, safety studywith no specific hypothesesdefined, so
no formal sample sizecalculation was made. However, the probabilityof at
leastone patientexperiencinga specific AE with an incidencerate of 5% is
>99% with 120 patients and the probability with an incidence rate of only
1% is 70.1%. A planned sample size of 150 patients was, therefore,
deemed to be adequate to evaluate the safety of FCM in this study.
Safety and efficacy were analysed using descriptive statistics, and for
specific variables, 95% confidence intervals (95% CIs) were also used.
These 95% CIs were calculated according to the method of Wilson as re-
commended by Altman et al. [18] for binary data, and as mean ± SE × t for
continuous data where SE is the standard error of the mean and t is the
upper 97.5 percentile of the appropriate t-distribution. Analyses were per-
formed on observed values only. Analyses of safety data were performed
using the safety population (all enrolled patients); efficacy results are de-
scribed using the intent-to-treat (ITT) population (all enrolled patients who
received at least one dose of study medication).
Results
Study patients
Patient recruitment began in July 2003; the final follow-up
assessment visit took place in May 2004. A total of 344
patients were screened, of whom 163 (47.4%) comprised
the safety population and 162 were included in the ITT
population. In total, 150 out of 163 (92.0%) patients com-
pleted the study (Figure 1).
The majority of patients were Caucasian, with more men
(56.4%) than women enrolled to the study (safety popula-
tion; Table 1). The most common primary renal diseasewas
glomerulopathy [77 out of 163 (47.2%) patients]. Over
three-quarters of the patients were undergoing three HD
sessions per week [134 out of 163 (82.2%)], the mean dur-
ation of HD was 3.2 years [range, 1–23 years]. Nearly
three-quarters of the patients [120 out of 163 (73.6%)] were
receiving a stable dose of concomitant ESAs at baseline
and for the duration of the study. Individual calculated iron
deficits ranged from 933 to 2169 mg.
Treatment
At all HD sessions, 100 or 200 mg of iron as FCM was
administered, to a mean total cumulative dose of 2133.3 ±
57.7 mg at HD Session 11. The mean dose of FCM admi-
nisteredwas200mgironforthefirstfourHDsessions,with
a mean for subsequent infusions ranging between 196.2 mg
(HD Session 5) and 160.0 mg (HD Sessions 9 and 10). Five
patients cumulatively received more iron [9, 41, 100 (two
patients) and 600 mg, respectively) than their calculated re-
quirements. None of these patients developed any adverse
clinicalsymptomsandonlyonepatientwithaserumferritin
level of 620 μg/l was subsequently withdrawn from the
study.
The mean overall duration of the therapeutic period was
15.9 ± 4.5 days (minimum duration, 3 days; maximum
duration, 31 days). The highest cumulative total iron dose
administered was 2200 mg in one patient who underwent
11 HD sessions at ∼3-day intervals.
All patients who were receiving ESAs at baseline (ran-
ging from 2000 IU once weekly to 10 000 IU twice
weekly) maintained a stable dose throughout the study.
Fig. 1. Flow of patients through the study.
Table 1. Patient demographics and baseline characteristics (safety
population; n = 163)
Safety population
Age, years 44.9 ± 12.7
Sex
Female 71 (43.6%)
Male 92 (56.4%)
Race
Caucasian 113 (69.3%)
Asian 5 (3.1%)
Black 20 (12.3%)
Mixed race 25 (15.3%)
Height, cm 168.3 ± 9.1
Weight, kg 70.8 ± 15.8
Primary renal disease
Glomerulopathy 77 (47.2%)
Vascular nephropathy 9 (5.5%)
Interstitial nephropathy 19 (11.7%)
Other 58 (35.6%)
Number of weekly HD sessions
2 29 (17.8%)
3 134 (82.2%)
Patients receiving ESAs 120 (73.6%)
Duration of HD, years 3.2 ± 3.0
Hb,
a g/dl 9.1 ± 1.3
Serum ferritin,
a μg/l 67.3 ± 106.7
TSAT,
a % 17.4 ± 9.1
Values are expressed as mean ± standard deviation or number (percent)
ESAs, erythropoiesis-stimulating agents; Hb, haemoglobin; TSAT,
transferrin saturation.
aITT population, Hb, n = 159; serum ferritin and TSAT, n = 145.
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Adverse events. Intravenous iron as FCM was well-toler-
atedbypatientsinthisstudy.Intotal,193AEswerereported
in89outof163patients(54.6%;safetypopulation;Table2).
This incidence of AEs is as expected for a population of
chronically ill, multi-morbid patients. The most commonly
reportedAEsaredetailedinTable3.AtleastoneseriousAE
wasreportedin12outof163(7.4%)patients(Table4).This
number includes two patients who died (one from lung tu-
berculosisandonefromacuteheartfailure); noneoftheser-
ious AEs were considered by the investigators to be related
to the study medication. Three patients underwent renal
transplantation during the study. AEs that were considered
by the investigators to be possiblyrelated to the study medi-
cation were reported in 13 out of 163 (8.0%) patients, these
were nausea, abdominal pain, constipation, eructation,
whitebloodcellcountincrease,headache,nightsweats,pig-
mentation disorder, hypertension and hypotension; other
AEs related to laboratory parameters and included two re-
ports of increased alanine aminotransferase levels and one
each of aspartate aminotransferase increase, liver function
test abnormality and CRP increase. Only three out of 163
(1.8%) patients reported AEs (nausea, abnormal liver func-
tion test and headache) that were considered by the investi-
gators as probably related to study medication.
Five patients (3.1%) were withdrawn from the study pre-
maturely because of an AE (Table 2), these AEs were
bronchopneumonia (n = 1), respiratory tract infection with
hypertensive episode (n = 1), increased transaminases (n =
1) and renal transplant (n = 2).
There were five cases of accidental overdose, two of
which, in patients who received 100 mg iron as FCM, were
considered as certainly related to study treatment, but were
not reported as AEs and were not part of the AE statistical
analysis. The other three cases were reported as AEs and
included in the statistical analysis. None of the five pa-
tients developed clinical symptoms.
Clinical evaluations. No clinically relevant changes from
baseline or during HD sessions in vital signs (blood pres-
sure, heart rate and axillary temperature), physical exami-
nations or ECGs were observed.
Red blood cell and haematocrit values demonstrated an
improvement during the study; there were no clinically
relevant changes from baseline in reticulocytes. In addition,
no clinically relevant changes from baseline in liver func-
tion-related clinical chemistry parameters were observed.
MeanCRPvalueswereabovethenormalrange(0–5mg /l)
at all visits, except at screening and the 4-week post-base-
line visit. Mildly increased CRP values have frequently
been described in patients undergoing HD in the absence
of infection or inflammation. CRP increases were recorded
in four patients. In one patient, the high CRP value was not
due to any underlying clinical condition. The CRP value at
the local laboratory was 4 mg/l at baseline, 20 mg/l at
Table 2. Overview of AEs (safety population; n = 163)
Number (%) of patients
experiencing event
At least one AE 89 (54.6)
AEs by worst severity
Mild 54 (33.1)
Moderate 26 (16.0)
Severe 8 (4.9)
Unknown 1 (0.6)
At least one serious AE 12 (7.4)
AEs by relation to study drug
Unrelated or unlikely to be related 73 (44.8)
Possibly or probably related 16 (9.8)
Certainly related 0
Discontinuation of study medication 1 (0.6)
Unexpected worsening of pre-existing disease 4 (2.4)
AE
Death 2 (1.2)
AE, adverse event.
Two cases of overdose not reported as AEs and not included in the
analysis.
Table 3. Incidence of AEs reported in ≥5 patients (safety population;
n = 163)
Body system/preferred term
Number (%) of patients
experiencing event
At least one AE 89 (54.6)
Infections and infestations 24 (14.7)
Respiratory tract viral infection 6 (3.7)
Vascular disorders 21 (12.9)
Hypertension 13 (8.0)
Hypotension 8 (4.9)
Gastrointestinal disorders 18 (11.0)
Nausea 5 (3.1)
Investigations (laboratory and ECG abnormalities)15 (9.2)
Nervous system disorders 15 (9.2)
Headache 13 (8.0)
Musculoskeletal and connective tissue disorders 13 (8.0)
Muscle cramp 8 (4.9)
Respiratory, thoracic and mediastinal disorders 8 (4.9)
Injury, poisoning and procedural complications 5 (3.1)
General disorders and administration-site
conditions
7 (4.3)
Skin and subcutaneous tissue disorders 5 (3.1)
Surgical and medical procedures 5 (3.1)
AE, adverse event; ECG, electrocardiogram.
Table 4. Summary of serious AEs (safety population; n = 163)
Body system/preferred term
Number (%) of patients
experiencing event
At least one serious AE 12 (7.4)
Infections and infestations 4 (2.5)
Gastrointestinal disorders 3 (1.8)
Surgical and medical procedures 3 (1.8)
Renal transplantation 3 (1.8)
Vascular disorders 2 (1.2)
Cardiac disorders 1 (0.6)
General disorders and administration-site
conditions
1 (0.6)
Psychiatric disorders 1 (0.6)
Respiratory, thoracic and mediastinal disorders 1 (0.6)
AE, adverse event.
Ferric carboxymaltose in anaemic patients undergoing haemodialysis 27252 weeks following last administration, 16 mg/l at 4 weeks
following last administration and 7 mg/l at the post-treat-
ment follow-up assessment. The event was considered by
the investigator to be possibly related to study medication
and mild in intensity. For the other three patients, the events
were considered by the investigator to be unrelated to the
study medication.
Iron status safety thresholds. Iron status safety thresholds
of TSAT >50% or serum ferritin >500 μg/l were exceeded
by 28 out of 125 (22.4%) and 55 out of 125 (44.0%) pa-
tients, respectively, 2 weeks after the first administration of
study medication (safety population, only patients with
non-missing measurements), decreasing to seven out of
141 (5.0%) and 22 out of 141 (15.6%) patients, respective-
ly, by the post-treatment follow-up assessment. Of these,
treatment with i.v. iron as FCM was halted in only 10
out of 163 (6.1%) patients as their serum ferritin levels ex-
ceeded 500 μg/l. One patient, who was given an accidental
overdose (600 mg iron as FCM), reached a serum ferritin
level of 620 μg/l during the treatment period (and TSATof
54%) and was withdrawn from the study, although no clin-
ical symptoms were reported. The investigator attributed
t h es u r p a s s e di r o ns a f e t yt h r e s h o l dt oa no v e r e s t i m a t i o n
of iron deficit at baseline. Two patients with serum ferritin
levels of 634.0 and 678.2 μg/l, respectively, did not halt
treatment with study medication as the stopping rules
were not followed. Transitory elevations in iron para-
meters (ferritin levels >800 μg/l) occurred in five out
of 163 (3.1%) patients at some point during the study.
However, only one patient was withdrawn due to a fer-
ritin level of 1649 μg/l; this was not associated with
any clinical symptoms.
Efficacy
The number of responders, measured by an increase from
baseline in Hb of ≥1.0 g/dl, increased at each visit and was
achieved by 100 out of 162 (61.7%) patients by the time of
the follow-up visit (ITT population; Figure 2). Mean Hb
levels increased from 9.1 ± 1.30 g/dl (95% CI = 8.86;
9.26) at baseline to 9.5 ± 1.34 g/dl (95% CI = 9.25;
9.72) at 2 weeks after the first administration of study
medication and continued to increase through the observa-
tion period to reach 10.3 ± 1.63 g/dl (95% CI = 10.06;
10.58) at follow-up (ITT population; Figure 3). The mean
change in Hb 2 weeks following the first administration of
study medication was 0.53 ± 0.75 g/dl (95% CI = 0.40;
0.67).
Both serum ferritin levels and TSATwere suboptimal at
baseline (67.3 ± 106.73 μg/l and 17.4 ± 9.10%, respective-
ly), as defined by international recommendations [1,19].
However, within the 2 weeks following the first administra-
tion of FCM, serum ferritin levels and TSAT had increased
towithin their respective target ranges (200–500 μg/l serum
ferritin and >20% TSAT) [19] for patients undergoing HD
(512.7 ± 241.36 μg/l and 38.4 ± 17.23%, respectively) and,
although decreasing slightly, remained in the target range
until the final follow-up visit (333.6 ± 209.05 μg/l and
31.0 ± 11.00%, respectively; ITT population; Figure 4).
Although no formal statistical analysis was planned, the
results were considered to be clinically relevant. These
Fig. 2. The cumulative proportion of treatment responders patients attaining an increase in Hb = 1.0 g/dl and classified as treatment responders over
time (ITT population, N = 162).
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Discussion
Patients undergoing HD are unable to maintain their iron
balance because of chronic blood (and, therefore, iron) loss
at each dialysis session. The initial levels of Hb would indi-
cate that, despite the widespread use of ESAs, although in
relatively low doses, reduced iron levels and baseline in-
flammatory status contributed to the incomplete response
to ESA therapy. The initial levels were below the target
set for patients with CKD [1]. However, according to the
Kidney Disease Outcomes Quality Initiative (KDOQI)
2007 guidelines [19], in patients undergoing HD receiving
ESAtherapywithaHbtargetintherangeof11.0–12.0g/dl,
the proportion of patients who achieve this target in a single
month may be 30% or less [19]. Using the National Health
and Nutritional Examination Survey, it was found that low
levels of iron (serum ferritin <100 μg/l or TSAT <20%)
werepresentinthemajorityofpatientswithCKDnotunder-
going dialysis with reduced creatinine clearance [20] and
was associated with absent bone marrow iron in ∼80% of
patients [21].
HD induces an inflammatory state that accounts for the
associated increased serum hepcidin levels [22]. Hepcidin
blocks iron absorption from the duodenum and iron re-
lease from the liver (the main iron store) and macro-
phages, thereby interrupting iron recycling [4,23]. The
decreased availability of iron for erythropoiesis aggra-
vates the existing anaemia of chronic disease (functional
iron deficiency) in HD patients. Oral iron therapy does
not lead to normalization of iron stores, as it is not
well-absorbed, is poorly tolerated and is associated with
low compliance [1,24]. Therefore, in order to maintain
an optimal iron status, it is strongly recommended that
patients with CKD who are undergoing HD receive sup-
plemental iron intravenously rather than orally [1,19].
This study demonstrates that 200 mg i.v. iron as FCM,
administered by bolus–push injection into the HD venous
line, is both well-tolerated and effective in increasing Hb
levels and iron stores for patients undergoing HD who re-
quire treatment for IDA. The majority of patients (61.7%)
were treatment responders, achieving a clinically relevant
increase in Hb levels of ≥1.0 g/dl at any time during the
study after receiving iron as FCM. The observed clinically
relevant increases in Hb levels (from 9.1 g/dl at baseline to
10.3 g/dl by the follow-up visit) in the majority of patients
can be solely attributed to the administration of i.v. iron as
FCM, as changes in anaemia treatment such as increases in
the dosage of ESAs were not permitted during the trial.
There is concern, however, among medical personnel
regarding the safety of earlier formulations of parenteral
iron. These concerns primarily relate to the potential for
excess iron to produce reactive oxygen species that can
increase oxidative tissue damage in patients with chronic
inflammatory disease: vasoactive reactions that may occur
when larger doses of i.v. iron are administered quickly
and the incidence of anaphylactic reactions (occasion-
ally fatal) that occur as a consequence of pre-formed
anti-dextran antibodies to i.v. iron dextran [1].
In this study, over 90% of participating patients com-
pleted iron supplementation with FCM. As expected for a
Fig. 3. Mean (SE) levels of Hb (in grammes per decilitre) over time (ITT population, N = 162).
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than half of the patients (54.6%) reported an AE. However,
<10% of the patients [16 out of 163 (9.8%)] reported an AE
considered by the investigators to be possibly or probably
related to study medication, and neither of the two deaths
that occurred during the study was considered to be related
tostudymedication.ThemostfrequentlyreportedAEswere
respiratory tract viral infection, hypertension, hypotension,
Fig. 4. Mean (SE) (a) serum ferritin (in microgrammes per litre) and (b) TSAT (in percent) values over time (ITT population, N = 162).
2728 A. Covic and G. Mircescumuscle cramps, nausea and headache. Therewere no clinic-
allyrelevantchangesinvitalsignsorphysicalexaminations.
Another recently developed i.v. iron formulation, feru-
moxytol, may be also applied by rapid i.v. injections (two
doses of 510 mg iron may be given 3–8 days apart), but
in contrast to FCM, it contains dextran derivatives [25].
Significantly increased Hb levels in comparison to oral
iron were reported in Phase III trials involving patients
with CKD requiring HD [26] as well as patients not on
dialysis [27].
The main limitation of this study was its open-label,
single-arm design. However, as the primary aim was to
evaluate safety, and efficacy was assessed by laboratory
parameters, no comparator was necessary. Nevertheless,
it may be difficult to conclude the extent to which the
reported AEs are related to the study treatment rather
than the effects of HD.
In a Phase I dose-escalation study, up to 1000 mg iron as
FCM, given as an i.v. infusion over 15 min for doses of
over 100 mg iron, was well-tolerated in patients with mild
IDA [15]. Recently presented clinical data also support the
favourable safety and efficacy profile of i.v. iron as FCM
[28,29]. Studies have demonstrated that, compared with
oral (FeSO4) or i.v. iron as iron sucrose, significant im-
provements in Hb levels can be achieved with i.v. iron
as FCM in both anaemic patients with non-dialysis-
dependent CKD [28] and in HD patients with IDA [29].
Furthermore, treatment with iron as FCM resulted in a
lower incidence of drug-related AEs during treatment com-
pared with the earlier supplemental iron preparations [30].
According to Geisser et al. [13], the toxic effects of an
iron complex can be forecast by the physiochemical proper-
ties (molecular mass, kinetic and thermodynamic stability)
of the compound. FCM is a strong and robust iron complex
and, as such, demonstrates the properties of an ideal iron
compound. Owing to the high structural homogeneity and
slow degradation kinetics of FCM, i.v. administration re-
sults in a low toxicity and targeted delivery of iron to the
reticuloendothelial system and its distribution to the bone
marrow, liver and spleen [4,14]. In a second step, the com-
plexis metabolized and the iron is slowly and competitively
delivered to endogenous iron-binding proteins. The reticu-
loendothelial uptake is thought to illustrate, indirectly, the
safety of i.v. iron polysaccharide complexes with regard to
thelong-termeffectsontheparenchymaofdifferentorgans.
Conclusion
In conclusion, i.v. iron as FCM administered by bolus–
push injection was well-tolerated in this safety study with
a population of anaemic patients undergoing HD. The in-
cidence of AEs reported during the study was as expected
for a chronically ill patient population, and no new safety
concerns were raised. None of the serious AEs and none of
the AEs that led to discontinuation of the study medication
were considered related to FCM. Furthermore, FCM was
effective in correcting anaemia and refilling the iron stores
of this population, which translated into a clinically mean-
ingful increase in Hb, TSATand serum ferritin levels. This
study supports FCM as a new treatment for IDA, offering
patients an effective supplemental iron formulation with a
good safety profile.
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Abstract
Background. T-cell damage by increased oxidative
stress in end-stage renal disease (ESRD) patients under-
going chronic haemodialysis (HD) led to the increased
T-cell apoptosis and the alteration of surface markers
and Th1/Th2 ratio in CD4
+ T lymphocytes. Antioxidant
electrolysed-reduced water (ERW) was used as the dialys-
ate in ESRD patients undergoing chronic HD to test for
improved oxidative stress-related T-cell apoptosis, altera-
tions of surface markers and intracellular cytokine profile.
Methods. We evaluated apoptosis formation by annexin V ,
CD25-related surface markers, and cytokine ratio of Th1/Th2
in CD4
+ T lymphocytes and Tc1/Tc2 in CD8
+ T lymphocytes
of 42 ESRD patients haemodialysed with ERW for 1 year.
Results. In comparison to 12 healthy individuals, the
ESRD patients had more T-cell apoptosis and less CD3
+,
CD4
+ and CD8
+ T cells and CD25/CD69/CD94/CD3
+
phenotypes at baseline. Lower intracellular IL-2 and IFN-
γ levels in the Th1/CD4
+ and Tc1/CD8
+ cells and higher
intracellular IL-4, IL-6 and IL-10 levels in the Th2/CD4
+
and Tc2/CD8
+ cells were also noted in the ESRD patients.
After a 1-year ERW treatment, the patients had a decrease
in T-cell apoptosis and increases in CD3
+, CD4
+ and CD8
+
cell numbers and CD25/CD69/CD94/CD3
+ phenotypes in
the T cells. The intracellular IL-2 and IFN-γ levels in the
Th1/Tc1 cells significantly (P < 0.05) increased and the
intracellular IL-4, IL-6 and IL-10 levels in the Th2/Tc2
cells decreased. Furthermore, the Th1/Th2 and Tc1/Tc2
cytokine ratios were improved toward a normal status.
Conclusion. One-year ERW treatment effectively amelio-
ratedT-cellapoptosis,alteredCD25-relatedsurfacemarkers
and intracellular cytokine profile in the HD patients.
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